文献速递妇科

新辅助化疗联合或不联合尼达尼布治疗晚期上皮性卵巢癌:GINECO双盲随机II期CHIVA试验的启示

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
PubMed 文献 · Gynecol Oncol · 2023-01-25

CHIVA试验将188例不可切除的FIGO IIIC-IV期上皮性卵巢癌患者随机分配至尼达尼布组(124例)或安慰剂组(64例),在紫杉醇+卡铂新辅助化疗期间及维持治疗中加用尼达尼布或安慰剂。结果显示尼达尼布组无进展生存期(中位14.4个月 vs 16.8个月,HR 1.50,p=0.02)和总生存期(中位37.7个月 vs 44.1个月,HR 1.54,p=0.054)均劣于安慰剂组,且毒性增加、中间性减瘤术可行性降低。

要点

  • 尼达尼布联合新辅助化疗组中位无进展生存期为14.4个月,安慰剂组为16.8个月(HR 1.50,p=0.02)。
  • 尼达尼布组3/4级不良事件发生率为92%,安慰剂组为69%,以血液学和胃肠道毒性为主。
  • 尼达尼布组中间性减瘤术可行性为58%,安慰剂组为77%;RECIST缓解率分别为35%和56%。

核心结论

  • 在晚期上皮性卵巢癌的新辅助化疗及维持治疗中加入尼达尼布不能作为推荐,因其增加毒性并损害化疗疗效(中间性减瘤术可行性、无进展生存期、总生存期)。

研究设计与样本

  • 随机双盲II期CHIVA试验(NCT01583322),2013年1月至2015年5月纳入188例新诊断不可切除的FIGO IIIC-IV期上皮性卵巢癌患者,按2:1随机分配至尼达尼布组(124例)或安慰剂组(64例)。
  • 患者接受3-4周期卡铂+紫杉醇每3周方案新辅助化疗,随后行中间性减瘤术,术后再接受2-3周期化疗。
  • 尼达尼布200 mg每日两次,每3周周期的第2-21天给药(围手术期周期省略),随后维持治疗最长2年;主要终点为无进展生存期。

主要发现

  • 尼达尼布组中位无进展生存期为14.4个月,安慰剂组为16.8个月(风险比1.50,p=0.02)。
  • 尼达尼布组中位总生存期为37.7个月,安慰剂组为44.1个月(风险比1.54,p=0.054)。
  • 尼达尼布组3/4级不良事件发生率为92%,安慰剂组为69%,以血液学和胃肠道毒性为主。
  • 中间性减瘤术前RECIST缓解率尼达尼布组为35%,安慰剂组为56%。
  • 中间性减瘤术可行性尼达尼布组为58%,安慰剂组为77%。

关键数值与推荐

  • 尼达尼布给药方案:200 mg每日两次,每3周周期的第2-21天给药(围手术期周期省略),维持治疗最长2年。
  • 新辅助化疗方案:卡铂+紫杉醇每3周,术前3-4周期,术后2-3周期。

临床怎么用

  • 作者认为,在晚期上皮性卵巢癌的新辅助化疗和维持治疗中加入尼达尼布不能作为推荐,因其增加毒性并损害化疗疗效(中间性减瘤术可行性、无进展生存期、总生存期)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The oral anti-angiogenic therapy nintedanib prolongs progression-free survival (PFS) when combined with chemotherapy after primary surgery for advanced epithelial ovarian cancer. The randomized phase II CHIVA trial evaluated the impact of combining nintedanib with neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer. METHODS: Patients with newly diagnosed unresectable FIGO stage IIIC-IV epithelial ovarian cancer received 3-4 cycles of carboplatin plus paclitaxel every 3 weeks as NACT before interval debulking surgery (IDS), followed by 2-3 post-operative cycles. Patients were randomized 2:1 to receive either nintedanib 200 mg twice daily or placebo on days 2-21 every 3 weeks during NACT (omitting peri-operative cycles), and then as maintenance therapy for up to 2 years. The primary endpoint was PFS. RESULTS: Between January 2013 and May 2015, 188 patients were randomized (124 to nintedanib, 64 to placebo). PFS was significantly inferior with nintedanib (median 14.4 versus 16.8 months with placebo; hazard ratio 1.50, p = 0.02). Overall survival (OS) was also inferior (median 37.7 versus 44.1 months, respectively; hazard ratio 1.54, p = 0.054). Nintedanib was associated with increased toxicity (grade 3/4 adverse events: 92% versus 69%, predominantly hematologic and gastrointestinal), lower response rate by RECIST (35% versus 56% before IDS), and lower IDS feasibility (58% versus 77%) versus placebo. CONCLUSIONS: Adding nintedanib to chemotherapy and in maintenance as part of NACT for advanced epithelial ovarian cancer cannot be recommended as it increases toxicity and compromises chemotherapy efficacy (IDS, PFS, OS). CLINICALTRIALS: govregistration: NCT01583322.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ferron G, De Rauglaudre G, Becourt S, et al. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial. Gynecol Oncol. 2023. PMID: 36706645. doi:10.1016/j.ygyno.2023.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。